Seite 1 von 5
Neuester Beitrag: 03.02.20 19:44
|Eröffnet am:||05.11.18 18:40||von: Vassago||Anzahl Beiträge:||110|
|Neuester Beitrag:||03.02.20 19:44||von: Balu4u||Leser gesamt:||11.080|
|Seite: < | 2 | 3 | 4 | 5 5 >|
"At September 30, 2018, Clearside had cash, cash equivalents and short-term investments totaling $64.9 million. Based on that, Clearside’s current research and development plans, including its planned discontinuation of its clinical development programs for combination therapy in RVO and DME, and its anticipated available borrowing capacity under its debt facility, Clearside believes it will have sufficient resources to fund its planned operations into the first quarter of 2020."
Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection with PDUFA Date Set for October 19, 2019
Cash, cash equivalents and short-term investments totaled $40.9 million as of December 31, 2018. Since then, Clearside has augmented its year-end 2018 cash balance with $5.6 million of net proceeds from sales of common stock under its at-the-market facility.
We have entered into a certain sales agreement, or the sales agreement, with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $50.0 million from time to time through Cowen.
Die haben jetzt angefangen zu verkaufen.
As of March 14, 2019, we have sold 3,927,541 shares of our common stock for gross proceeds of $5.8 million under the sales agreement pursuant to our prospectus dated July 13, 2017, or the Prospectus, which leaves $44.2 million of common stock available under the sales agreement.
at a price of $1.74 per share
Wenn sie alle zu 1,74$ verkaufen gibt es 25,4Mio Aktien dazu!
Totaler Unfug! Danke Clintfür #22.
We are now subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement of which this prospectus supplement and the Prospectus form a part.
Clerside musste das Prospekt anpassen, von 50Mio$ auf noch $18,543,269$.
Daher auch dieser Prospektnachtrag.( 424B5 )
Beim Verkauf der Aktien wird kein Prospekt ausgegeben, dafür steht schon das Prospekt.
Gut es sind jetzt 18,5 und nicht mehr 50 Mio$ die sie verkaufen dürfen. Ist doch positiv, oder?
Der Kurs 1,47$ waren am Tag der Berechnung für den max. $ Betrag der verkauft werden darf.
Das ATM kann jeder Zeit zu jedem Kurs durchgeführt werden, es sei denn es gibt eine Beschränkung im sales agreement.
6. Limited Primary Offerings by Certain Other Registrants. Securities to be offered for cash by or on behalf of a registrant; provided that:(a)the aggregate market value of securities sold by or on behalf of the registrant pursuant to this Instruction I.B.6. during the period of 12 calendar months immediately prior to, and including, the sale is no more than one-third of the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant;(b) the registrant is not a shell company (as defined in §230.405 of this chapter) and has not been a shell company for at least 12 calendar months previously and if it has been a shell company at any time previ ously, has filed current Form 10 information with the Commission at least 12 calendar months previously reflecting its status as an entity that is not a shell company; and(c) the registrant has at least one class of common equity securities listed and registered on a national securities exchange
Die dürfen nicht mehr Aktien verkaufen! Geregelt durch UNITED STATESSECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
The aggregate market value of our common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is $55,629,809.70, which was calculated based on 31,971,155 shares of our outstanding common stock held by non-affiliates on March 14, 2019 at a price of $1.74 per share, the closing price of our common stock on February 20, 2019. During the 12 calendar months prior to, and including, the date of this prospectus supplement, we have not sold any securities pursuant to General Instruction I.B.6 of Form S-3. As a result of the limitations of General Instruction I.B.6, and in accordance with the terms of the sales agreement, we are registering the offer and sale of shares of our common stock having an aggregate offering price of up to $18,543,269 from time to time through Cowen.
market value $55,629,809.70 : 3 = 18,543,269.9$
Sie dürfen in 12 Monaten nur 1/3 des market value an Aktien verkaufen.